Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apocynin, also known as acetovanillone, is a naturally occurring methoxy-substituted catechol isolated from various plant sources. It is experimentally used as an inhibitor of NADPH oxidase, which plays a key role in the production of reactive oxygen species (ROS) by activated neutrophils and macrophages. Apocynin exerts anti-inflammatory and antioxidant effects by inhibiting the assembly of the NADPH oxidase complex, thereby reducing ROS production. It has been investigated for its potential therapeutic effects in conditions such as bronchial asthma, chronic obstructive pulmonary disease (COPD), arthritis, bowel disease, atherosclerosis, familial ALS (amyotrophic lateral sclerosis), and neuroprotection in models of stroke and Parkinson's disease[2][3][5]. In traditional medicine (e.g., Ayurveda), it has been used to treat heart problems and diseases[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on apocynin.